1. Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

3. Radionuclides in mCRPC and Bone Metastases

4. Beta-Emitting Radionuclides Pain Intensity and Symptomatic Skeletal Events

6. Properties of Alpha- and Beta-Emitting Radionuclides

7. ALSYMPCA Trial Design

8. ALSYMPCA Overall Survival

10. ALSYMPCA Subgroup Analysis Overall Survival

11. ALSYMPCA Subgroup Analysis Time to First Symptomatic Skeletal Event

12. EAP -- Baseline ALP Is an Adverse Risk Factor

13. ALP Declines at 12 Weeks Important Prognostic Indicator for OS

14. ALSYMPCA Safety Data

16. Radium-223 Plus Docetaxel (cont)

17. Docetaxel ± Radium-223 Rates of PSA Decline

18. Docetaxel ± Radium-223 Rates of ALP Decline

19. Radium-223 Plus Denosumab

20. Radium-223 Plus Abiraterone

21. Radium-223 Plus Abiraterone and/or Enzalutamide

22. Radium-223 Survival Based on Number of Injections

23. Radium-223 Survival Based on Number of Doses

24. Effect of Radium-223 on Bone Pain

25. Effect of Pre-Treatment on Number of Radium-223 Cycles Received

26. Predictors for Receiving 1 to 4 vs 5 to 6 Radium-223 Cycles

27. Ongoing Clinical Trials

28. Conclusions and Clinical Pearls

29. Abbreviations

30. Abbreviations (cont)